CDEK
← All drugs Report issue

porcine brain-derived peptide preparation

Trade name: cerebrolysin

Animal productexperimental

Cerebrolysin is an experimental mixture of enzymatically-treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Although it is under preliminary study for its potential to treat various brain diseases, it is used as a therapy in dozens of countries in Eurasia. — Wikipedia

Clinical trial activity

28 trials · 30 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
8
Phase 3
4
Phase 4
10

Earliest trial started Oct 1, 2004 (NCT00911807)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cerebrolysin
  • cerebrolysin
  • cerebrolysine
  • fpf1070
  • fpf 1070

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06899464Phase 4Oct 1, 2025Cardinal Stefan Wyszyński Institute of Cardiology
NCT07043686N/AJun 13, 2025University of Ljubljana
NCT06897176Phase 4Mar 12, 2025Yonsei University
NCT06489925Early Phase 1 (Phase 1)Jul 31, 2024Ever Neuro Pharma GmbH, University Hospital "Sestre Milosrdnice"
NCT06339411Early Phase 1 (Phase 1)May 1, 2024Chang Gung University
NCT06677502N/AJan 1, 2024Medical University of Lublin
NCT05755997Phase 2Nov 29, 2023Charles University, Ever Neuro Pharma GmbH, XClinical GmbH
NCT06070753N/AOct 1, 2023Hebrew University
NCT06052787Phase 3Sep 1, 2023Ain Shams University
NCT05821075Phase 1/Phase 2 (Phase 2)Apr 24, 2023October 6 University
NCT05864677N/AJan 15, 2023Medical University of Lublin
NCT06078215Phase 4Jan 10, 2023Poznan University
NCT06273020Phase 4Nov 17, 2022Ever Neuro Pharma GmbH, Universidad Autonoma de Nuevo Leon
NCT06208540Phase 4Aug 30, 2021Assiut University
NCT04913831Phase 4Jun 30, 2021Yonsei University
NCT05124353Phase 2/Phase 3 (Phase 3)Apr 27, 2021Pomeranian Medical University
NCT04904341Phase 3Jan 1, 2021Brainomix, Government of Poland
NCT04830943Phase 4Aug 1, 2020Assiut University
NCT04427241Phase 4Jul 31, 2020Ever Neuro Pharma GmbH, Konkuk University
NCT04124367Phase 2Nov 30, 2019Evaluation Software Development GmbH, Ever Neuro Pharma GmbH, Klinik Pirawarth, NeuroConn GmbH, VascAge GmbH
Showing 20 of 28 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ever Neuro Pharma GmbHFor profit6332004
Ain Shams UniversityAcademic/Hospital2222011
Assiut UniversityAcademic/Hospital2212020
Mansoura UniversityAcademic/Hospital2222016
Medical University of LublinAcademic/Hospital2212023
Universidad Autonoma de Nuevo LeonAcademic/Hospital2222014
Yonsei UniversityAcademic/Hospital2212021
acromion GmbHFor profit1012004
BrainomixFor profit1012021
Cardinal Stefan Wyszyński Institute of CardiologyAcademic/Hospital1112025
Chang Gung UniversityAcademic/Hospital1112024
Charles UniversityAcademic/Hospital1012023
Clinical Institute of the Brain, RussiaAcademic/Hospital1112015
EBEWE PharmaFor profit1012004
EuroEspes Biomedical Research CenterAcademic/Hospital1012004
Evaluation Software Development GmbHFor profit1012019
Government of PolandGovernment1112021
Hebrew UniversityAcademic/Hospital1112023
Klinik PirawarthAcademic/Hospital1012019
Konkuk UniversityAcademic/Hospital1112020
30 organizations
Page 1 / 2